Genmab — Oktober 2024

[Vitus]

Uha, aktien “drøner” jo op …..

[JKY_VH]

alt er jo relativt, men overdrivelse fremmer jo forståelsen:-)

[ProinvestorNEWS]

C25: Kan kvartalsregnskaberne rette op på pressede kurser? Forventninger til selskaberne: https://proinvestor.com/boards/122495

[E_L]

GEN3014; only about 3 centers are still recruiting, rest is 'Active, not recruiting' or terminated, expected Primary Completion still october... https://clinicaltrials.gov/study/NCT04824794?tab=history&a=20&b=21&compareMode=sideBySide#version-content-panel

[gentogen]

Only 1 site outside US is still recruiting

[Bulder]

And U.S. is not involved in hehe

[Bulder]

H2H

[Bulder]

Det var stavekontrollen der lavede h2h om til hehe. Fandme ikke noget at grine ad.

[Vitus]

Neeej…..der er ikke meget “drøn” i Genmab…

[gentogen]

I øvrigt lidt af et puslespil med 17 lande i H2H: Fra Philippinerne til Georgien til Korea til Ukraine og Moldova etc.

[gentogen]

Kiggede af nysgerrighed lige på Genmabs patent. det hedder, at det dækker"include epidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracranial, intrathoracic, epidural and intrasternal injection and infusion."

[gentogen]

man må da sige, at de forsøgte at dække sig ind for enhver eventualitet...men Ak nej...

[gentogen]

https://patents.google.com/patent/US7829673B2/en

[E_L]

Er Genmab alt for billig? https://aktietip.dk/er-genmab-alt-for-billig/

[E_L]

Stockbull now writing for Zacks/Yahoo?? - -
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround https://finance.yahoo.com/news/down-14-68-4-weeks-133506234.html

[E_L]

IJGC podcast - Dr. Ignace Vergote to discuss Tisotumab Vidotin in Second- & Third-Line Recurrent Cervical https://open.spotify.com/episode/2YiCmRc3LC9soPRHt0g5nR

[E_L]

Hemab Therapeutics is actively enrolling a Phase 2 clinical trial of HMB-001, a subcutaneous injection designed to restore clot formation impaired by GT https://x.com/Hemab_Tx/status/1843973949782475135

[E_L]

Zacks Estimate Q3 24 For Darzalex, the consensus as well as our model estimates is pegged at $2.94 billion. https://ca.finance.yahoo.com/news/jnj-stock-portfolio-ahead-q3-190000402.html

[E_L]

small
new trial for Amivantamab in Malignant Brain Tumours (5G-EMERALD) https://clinicaltrials.gov/study/NCT06632236

[E_L]

I actually thought that due to its large molecular size amivantamab could not cross the blood-brain barrier , so a bit surprised. we'll see.